Mesa Laboratories vs Sypris Solutions
MLAB and SYPR side by side, both in laboratory apparatus and analytical, optical, measuring, and controlling instruments. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MLAB and SYPR compare
Mesa Laboratories is the larger company, worth 28 times as much as Sypris Solutions ($779M against $28.1M).
Mesa Laboratories grew revenue faster over the last twelve months (2.5% versus −11.5% for Sypris Solutions).
Mesa Laboratories keeps more of each dollar of sales as profit, with a net margin of 2.7% compared with −9.2% at Sypris Solutions.
Mesa Laboratories pays a dividend yielding 0.46%; Sypris Solutions does not pay one.
Mesa Laboratories scores higher on the StockData Score (11 against 2 for Sypris Solutions), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MLAB | SYPR |
|---|---|---|
| Size and price | ||
| Market cap | $779M | $28.1M |
| Share price | $139.21 | $1.22 |
| Change, 1 year | 70.1% | −43.0% |
| Change, 5 years | −55.4% | −59.9% |
| Beta (5Y) | 1.00 | 0.60 |
| Employees | 717 | 548 |
| StockData Score | ||
| Total score | 11 (better) | 2 |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 (better) | 0 |
| Performance score | 4 (better) | 0 |
| Health score | 1 | 1 |
| Dividend score | 4 (better) | 0 |
| Valuation | ||
| P/E | 121× | – |
| P/S | 3.1× | 0.2× (better) |
| P/B | 4.0× | 2.4× (better) |
| EV/EBITDA | 28.9× | – |
| P/FCF | 15.8× | – |
| PEG | 1.31 | – |
| FCF yield | 6.3% (better) | −10.5% |
| Fair value | $81.27 | – |
| Margin of safety | −71.3% | – |
| Growth | ||
| Revenue growth (TTM) | 2.5% (better) | −11.5% |
| Revenue growth, 5Y average | 13.2% (better) | 7.8% |
| EPS growth, 5Y average | 13.6% | – |
| Profitability | ||
| Gross margin | 64.8% (better) | 5.4% |
| Operating margin | 10.4% (better) | −9.6% |
| Net margin | 2.7% (better) | −9.2% |
| FCF margin | 19.7% (better) | −2.6% |
| Return on equity | 3.6% (better) | −69.9% |
| Return on invested capital | 7.9% (better) | −30.1% |
| Financial health | ||
| Debt / equity | – | 1.16 |
| Interest coverage | 2.6× (better) | −5.6× |
| Current ratio | 1.90 (better) | 1.26 |
| Altman Z-score | 2.54 (better) | −0.65 |
| Piotroski F-score | 8 (better) | 2 |
| Dividends and buybacks | ||
| Dividend yield | 0.46% (better) | 0.00% |
| Payout ratio | 53.3% | – |
| Years of dividend growth | 0 | 0 |
| Dividend growth, 5Y average | 0.00% | – |
| Shareholder yield | 0.46% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 89.9% | 19.0% |
| Held by insiders | 3.6% | 46.6% |
| Insider net buying, 12 months | −$216K | – |
| Short interest, % of float | 7.0% | 0.29% |
Go deeper
- MLAB stock overview
- MLAB income statement
- MLAB valuation and score
- SYPR stock overview
- SYPR income statement
- SYPR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.